GlassScriptPhysician profile
Michael Seth Rosman
NPI 1710335773
$7,428.88
in general payments reported to CMS, 2019-2025
27 companies · $3,839 in 2025
The $3,839 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.13 · 2023: $844 · 2024: $2,734 · 2025: $3,839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,416.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,450.03 | 2023-2025 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $1,390.48 | 2022-2025 | Rinvoq, Skyrizi, Viberzi |
| Janssen Biotech, INC. | $888.60 | 2023-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $585.07 | 2023-2025 | Entyvio, Gattex |
| Qol Medical, LLC | $564.67 | 2024-2025 | Sucraid, Sucraid |
| Pfizer INC. | $439.16 | 2024-2025 | |
| Ardelyx, INC. | $360.76 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $277.19 | 2023-2025 | Dupixent |
| Celltrion USA INC. | $238.92 | 2025 | Vegzelma |
| Genzyme Corporation | $187.95 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $185.50 | 2023-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $139.99 | 2024 | Zeposia |
| Lilly USA, LLC | $127.59 | 2023-2025 | Omvoh |
| Madrigal Pharmaceuticals | $85.42 | 2024-2025 | Resmetirom, Rezdiffra |
| Aimmune Therapeutics, INC. | $80.77 | 2024-2025 | Zenpep |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $79.85 | 2023-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $79.60 | 2023-2024 | Linzess |
| Ipsen Biopharmaceuticals, INC | $60.46 | 2025 | Iqirvo |
| Gilead Sciences, INC. | $42.46 | 2024-2025 | |
| Leo Pharma INC. | $32.38 | 2025 | Anzupgo |
| Evoke Pharma, INC. | $24.78 | 2025 | |
| Vibrant Gastro, INC. | $24.70 | 2025 | Vibrant Starter Kit |
| Galderma Laboratories, L.P. | $18.84 | 2025 | Nemluvio |
| Phadia US INC. | $17.59 | 2023 | Immunocap |
| Mayne Pharma Commercial LLC | $16.54 | 2025 | |
| Redhill Biopharma INC. | $15.76 | 2023 | Talicia |
| Amgen INC. | $13.82 | 2023 | Amjevita, Avsola |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rosman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.